Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough

NCT06504446 is registered in ClinicalTrials.gov with Nocion Therapeutics as lead sponsor.

NCT NCT06504446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06504446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough
Lead sponsor
Nocion Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 24, 2024
Completion date
June 29, 2026
Enrollment
455 (estimated)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or unexplained chronic cough